At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 444 enrolled
Drug / intervention
AMZ001 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Placebo-controlled, Double-blind, Randomized, Trial of AMZ001 for the Treatment of Knee Osteoarthritis Symptoms
In Brief
A Phase 3 clinical trial evaluating AMZ001, Placebo, and 1 other intervention for Osteoarthritis, Knee. Completed, enrolled 444 participants across 7 sites in 3 countries.
Detailed Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, 4-week trial of a formulation of AMZ001 once or twice daily versus placebo twice daily, including a single-blind treatment group with a commercial gel four times daily.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis, Knee
CountriesCzechia, Denmark, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartOct 2018
Primary CompletionJul 2019
TodayJul 2026
First PostedOct 2, 2018
Enrollment StartOct 4, 2018
Primary CompletionJul 9, 2019
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 7.8 years ago
Interventions
AMZ001drug
diclofenac gel
Placebodrug
Placebo
Comparatordrug
diclofenac gel